Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes
Open accessAbstract
This case-control study examines the use of glucagon-like peptide-1 receptor agonist before metabolic and bariatric surgery and its postoperative outcome.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GLP1-RAs may be used as part of the care pathway toward bariatric surgery to aid preoperative weight loss, potentially improving safety outcomes in surgery.
“GLP1-RAs may also be used as part of the care pathway toward bariatric surgery, to aid preoperative weight loss, potentially improving safety outcomes in surgery.93”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [93]
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kamarajah, S. K., Gudiozzi, N., Findlay, J. M., Lee, M. J., Pinkney, T., & Markar, S. R. (2025) · eClinicalMedicine · doi:10.1016/j.eclinm.2025.103408 · Cited by 29 · see citing works
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16 · see citing works
- Authors
- Mathur, V., Wasden, K., Shin, T. H., Medhati, P., Nimeri, A. A., Tavakkoli, A., & Sheu, E. G.
- Affiliations
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- JAMA Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2025-05-01
- Volume
- 160
- Issue
- 5
- Pages
- 594
- ISSN
- 2168-6254 (ISSN-L)
- OpenAlex
- W4408245863
- Cited by
- 30
- References
- 1
- Citations by year
- 2026: 17 · 2025: 13
- FWCI
- 28.22
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- JAMA Surgery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, GLP-1 receptor agonists, neoadjuvant therapy, bariatric surgery, weight loss, metabolic surgery, postoperative outcomes, obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
